Marc Tessier-Lavigne, Director at REGENERON PHARMACEUTICALS, INC. (REGN), sold 24,123 shares at $643.33 ($15.5M) on 2021-09-13, disclosed to the SEC on 2021-09-15.
Open-market sale of $15.5M REGN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $636.64 | 816 | $519K | 3.4% |
| 2 | $636.64 | 816 | $519K | 3.4% |
| 3 | $637.71 | 816 | $520K | 3.4% |
| 4 | $637.71 | 816 | $520K | 3.4% |
| 5 | $638.46 | 2,098 | $1.3M | 8.7% |
| 6 | $638.46 | 2,098 |
| $1.3M |
| 8.7% |
| 7 | $639.45 | 1,260 | $806K | 5.2% |
| 8 | $640.61 | 981 | $628K | 4.1% |
| 9 | $640.61 | 981 | $628K | 4.1% |
| 10 | $641.56 | 952 | $611K | 3.9% |
| 11 | $641.56 | 952 | $611K | 3.9% |
| 12 | $642.54 | 1,645 | $1.1M | 6.8% |
| 13 | $642.54 | 1,645 | $1.1M | 6.8% |
| 14 | $643.33 | 1,549 | $997K | 6.4% |
| 15 | $643.33 | 1,549 | $997K | 6.4% |
| 16 | $644.52 | 844 | $544K | 3.5% |
| 17 | $644.52 | 844 | $544K | 3.5% |
| 18 | $645.21 | 61 | $39K | 0.3% |
| 19 | $646.24 | 354 | $229K | 1.5% |
| 20 | $646.24 | 354 | $229K | 1.5% |
| 21 | $647.39 | 425 | $275K | 1.8% |
| 22 | $647.39 | 425 | $275K | 1.8% |
| 23 | $648.25 | 381 | $247K | 1.6% |
| 24 | $648.25 | 381 | $247K | 1.6% |
| 25 | $649.35 | 124 | $81K | 0.5% |
| 26 | $649.35 | 124 | $81K | 0.5% |
| 27 | $650.33 | 56 | $36K | 0.2% |
| 28 | $651.54 | 249 | $162K | 1.0% |
| 29 | $651.54 | 249 | $162K | 1.0% |
| 30 | $652.26 | 139 | $91K | 0.6% |
| 31 | $652.26 | 139 | $91K | 0.6% |
| Total | $641.80 avg | 24,123 | $15.5M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |